NIBR
POSTDOCTORAL PROGRAM

Jeffrey A. Engelman, M.D., Ph.D.

Dr. Jeff Engelman, Vice President and Global Head of Oncology, directs cancer drug discovery at the Novartis Institutes for BioMedical Research.

Oncologists now have an arsenal of tools, including therapies that target molecular changes in cancer cells and treatments that coax the immune system to fight tumors. The goal of NIBR Oncology—which collaborates closely with NIBR Immuno-oncology—is to bring together such therapies in combinations to unleash their full potential. The team also hopes to identify new tools and approaches to help more patients. NIBR researchers are aiming for cures in certain subtypes of cancer.

Jeff received his B.A. in Chemistry from Northwestern University in 1993 and his M.D. and Ph.D. from the Albert Einstein College of Medicine in 2000. He completed residency training in Internal Medicine at Brigham and Women’s Hospital, a fellowship in Hematology at Dana-Farber Cancer Institute, and postdoctoral research at Beth Israel Deaconess Medical Center. Before joining Novartis, he was Director of the Center for Thoracic Oncology and Molecular Therapeutics at Massachusetts General Hospital, where he studied responses to targeted therapies and mechanisms of resistance in lung cancer. He was also an Associate Professor at Harvard Medical School.

Focus on the patient, follow the science

At the earliest stages of Research, our drug discovery priorities are determined by patient need and sound science – not the potential market size of a medicine.